New combo shows promise for tough lung cancer
Disease control
Completed
This study tested a combination of two drugs, bemcentinib and pembrolizumab, in 99 people with advanced lung cancer that had already been treated. The goal was to see if the combo could shrink tumors. Participants were divided into groups based on their prior treatments. The stud…
Phase: PHASE2 • Sponsor: BerGenBio ASA • Aim: Disease control
Last updated May 26, 2026 12:01 UTC